Immunotherapy

Study Identifies Factors Associated With Outcomes After Dabrafenib + Trametinib

By

Despite the effectiveness of dabrafenib in combination with trametinib for metastatic BRAF-mutant melanoma, many patients experience disease progression that often leads to death. In this data analysis, researcher sought to identify clinical factors associated with long-term response and survival.

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

By

Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

By

In a multicenter, open-label, phase 2 study, researchers evaluated the activity and safety of vandetanib in patients with advanced RET-rearranged NSCLC.

Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma

Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma

By

Phase 2 studies have demonstrated that girentuximab possesses activity with a manageable safety profile for patients with clear cell renal cell carcinoma; therefore, in a phase 3 trial, researchers evaluated its efficacy and safety as adjuvant monotherapy.

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

By

Neurotoxicity is not uncommon in patients with melanoma treated with immune checkpoint inhibitors. In this study, therefore, researchers sought to examine the incidence of neurotoxicity across anti-CTLA-4 and anti-PD-1 antibodies at a single institution.

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

By

The addition of pembrolizumab to carboplatin and pemetrexed improves overall response rate compared with chemotherapy alone and has a manageable safety profile in patients with newly diagnosed advanced nonsquamous NSCLC.

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

By

Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.

HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma

HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma

By

Treatment with pembrolizumab better maintained health-related quality of life compared with chemotherapy in patients with advanced melanoma refractory to ipilimumab.

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

By

Antibacterial prophylaxis with the flouroquinolone, ciprofloxacin, substantially reduced the risk of bacteremia and neutropenic fever in patients with multiple myeloma or lymphoma undergoing high-dose chemotherapy and auto-HSCT.

Chemotherapy-Induced Dormancy Improves Immunotherapy for Breast Cancer

Chemotherapy-Induced Dormancy Improves Immunotherapy for Breast Cancer

By

Inducing quiescent dormancy with conventional chemotherapy makes cancer cells more susceptible to immunotherapy, thereby minimizing potential for tumor recurrence.

Managing IRAEs in Patients Receiving Checkpoint Inhibitors

Managing IRAEs in Patients Receiving Checkpoint Inhibitors

By

How should side effects of the new checkpoint inhibitor drugs be managed?

Experimental Drug Improves Immunotherapy Activity in Triple-Negative Breast Cancer

Experimental Drug Improves Immunotherapy Activity in Triple-Negative Breast Cancer

By

An experimental drug, AMPI-109, shows promise as an immunotherapy that sensitizes triple-negative breast cancer cells, enhancing the effectiveness of the drug.

Technique Maps Biomarkers That Predict Immunotherapy Response

Technique Maps Biomarkers That Predict Immunotherapy Response

By

With only 1 slide of a tumor section, an analysis of multiple tumor markers can be performed. The technique may help predict response to immunotherapy, which typically evokes responses in only a small group of patients.

Dual Antigen Targeting by CAR T Cells Improves Immunotherapeutic Technique

By

Chimeric antigen receptor (CAR) T cells may have improved therapeutic potential when they have 2 targets, according to preclinical findings using a mouse model.

Immunotherapy Combination is Effective in Colorectal Cancer

By

Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

By

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.

Study Better Characterizes Immunotherapy-related Skin Toxicities

By

Patients receiving PD-1 or PD-L1 antibodies exhibited papular and nodular eruptions with scale, as well as mucosal lesions with lichenoid features, that were typically manageable with topical steroid treatment.

Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer

Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer

By

A first-line triplet chemoimmunotherapy regimen comprised of paclitaxel, capecitabine, and bevacizumab followed by capecitabine and bevacizumab alone as maintenance therapy is highly active with a manageable safety profile in patients with triple-negative breast cancer.

Nivolumab Maintains Baseline HRQoL in Advanced Melanoma

Nivolumab Maintains Baseline HRQoL in Advanced Melanoma

By

In addition to improving overall survival compared with dacarbazine in patients with advanced melanoma, nivolumab maintains baseline levels of health-related quality of life to ultimately confer long-term quality of survival benefit.

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

By

Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

By

Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

By

Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.

Up to One-Quarter of Patients With Lung Cancer Ineligible for Immunotherapy

By

Fourteen percent to 25% of patients with lung cancer also have autoimmune disease. This comorbidity could make them unsuitable candidates for immunotherapy.

Disease-Free Status Is Achieved by Combining Immunotherapy Treatments in Patient With Metastatic Melanoma

By

A patient with refractory metastatic melanoma was successfully treated with a novel combination of 2 different types of immunotherapy.

Rituximab Maintenance Prolongs PFS in Patients With CLL

Rituximab Maintenance Prolongs PFS in Patients With CLL

By

New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.

Trastuzumab-related Cardiotoxicity Lower Among Taiwanese Patients

Trastuzumab-related Cardiotoxicity Lower Among Taiwanese Patients

By

Trastuzumab-related cardiotoxicity was far lower in Taiwanese women with breast cancer compared with previously published results, according to recent study data.

Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple Myeloma

By

Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.

Melanoma: Pembrolizumab Better Than Ipilimumab Regardless of PD-L1 Expression

Melanoma: Pembrolizumab Better Than Ipilimumab Regardless of PD-L1 Expression

By

Pembrolizumab provides benefit over ipilimumab in patients with advanced melanoma, regardless of tumor PD-L1 expression status or number of prior therapies, a study presented at the 2016 ASCO Annual Meeting has shown.

Genetic Subtypes of HLA Are Linked to Increased Overall Risk of Ovarian Cancer

By

Overall risk of developing ovarian cancer may be higher for women with certain types of human leukocyte antigen (HLA), which could underlie differences in their response to immunotherapy.

Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma

Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma

By

A third clinical trial is beginning for phase I testing of SurVaxM, a cancer vaccine. This trial tests for safety and effectiveness of the vaccine in combination with lenalidomide as maintenance therapy for adults with multiple myeloma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs